Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced...

from PR Newswire: https://ift.tt/3ChWU1K